Glucagon-Like Peptide 1
Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results
Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601
Semaglutide and Mental Health: A Complex Relationship
semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes
23andMe Shifts Focus to GLP-1 Telehealth Offering, Cuts Internal Drug Development Team
23andMe, GLP-1, telehealth, weight loss, drug development, layoffs
Hims Secures Drug Supply for Thriving Weight Loss Business
Hims, weight loss drugs, compounded GLP-1, drug supply, booming business, revenue growth, subscriber base
Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs
Novo Nordisk, GLP-1 drugs, compounded drugs, legal campaign, patient safety, semaglutide
Lilly’s Blockbuster GLP-1 Drugs Removed from FDA Shortage List
Lilly, GLP-1, FDA, drug shortage, Mounjaro, Zepbound, tirzepatide
Novo’s GLP-1 Liraglutide May Protect Brain from Alzheimer’s, New Study Finds
GLP-1, Liraglutide, Alzheimer’s Disease, Brain Protection, Cognitive Decline, Novo Nordisk
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1
Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition
, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,